0.88
+5.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immuron Ltd ADR
Its shares trade under the ticker IMRN. It has been listed since 9 June 2017. In the fiscal year to 30 June 2026, it reported revenue of $7.5m and a net loss of $3.8m. At that date it held total assets of $13.0m and shareholders' equity of $11.0m.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Jun 2017
- Employees
- 8
- Website
- immuron.com.au ↗
- Head office
- 62 LYGON STREET, CARLTON, VICTORIA, C3, 3053
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immuron Ltd ADR operates in the Health Care sector with Travelan and Protectyn products.
- The company has a strong R&D segment focusing on polyclonal antibodies for gastrointestinal disorders.
- Immuron collaborates with US Naval Medical Research Command for Campylobacter and E. coli treatments.
Weaknesses
- Immuron has only 8 employees, which may limit operational capacity.
- The company's products are limited to gastrointestinal health and digestive supplements.
- Immuron's clinical trials are in early stages with no commercialized products beyond Travelan.
Opportunities
- Immuron can expand its product line with IMM-529 in Phase II for C. difficile treatment.
- The US market offers significant potential for gastrointestinal health products.
- Collaborations with US institutions like Silver Spring, MD, USA can lead to new developments.
Threats
- Immuron faces competition from established pharmaceutical companies in the Health Care sector.
- The company's reliance on clinical trial success poses a significant risk to its business model.
- Immuron's small size and limited employee count may hinder its ability to compete effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.